View in EDS

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

Saved in:
Bibliographic Details
Title: First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
Authors: Schuler, Martin1 (AUTHOR) Martin.Schuler@uk-essen.de, Paz-Ares, Luis2 (AUTHOR) lpazaresr@seom.org, Sequist, Lecia V.3 (AUTHOR) lvsequist@partners.org, Hirsh, Vera4 (AUTHOR) vera.hirsh@muhc.mcgill.ca, Lee, Ki Hyeong5 (AUTHOR) kihlee@chungbuk.ac.kr, Wu, Yi-Long6 (AUTHOR) syylwu@live.cn, Lu, Shun7 (AUTHOR) shun_lu@hotmail.com, Zhou, Caicun8 (AUTHOR) caicunzhoudr@163.com, Feng, Jifeng9 (AUTHOR) fjif@vip.sina.com, Ellis, Stuart H.10 (AUTHOR) stuart.ellis@n-zero-1.co.uk, Samuelsen, Carl H.11 (AUTHOR) carl.samuelsen@boehringer-ingelheim.com, Tang, Wenbo12 (AUTHOR) wenbo.tang@boehringer-ingelheim.com, Märten, Angela13 (AUTHOR) angela.maerten@boehringer-ingelheim.com, Ehrnrooth, Eva14 (AUTHOR) evae@oncology.dk, Park, Keunchil15 (AUTHOR) kpark@skku.edu, Yang, James Chih-Hsin16 (AUTHOR) chihyang@ntu.edu.tw
Source: Lung Cancer (01695002). Jul2019, Vol. 133, p10-19. 10p.
Database: Academic Search Ultimate
Description
ISSN:01695002
DOI:10.1016/j.lungcan.2019.04.006